Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-AIO in Relapsed/Refractory B-cell Acute Lymphocytic Leukemia
NCT05292898Phase 1Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2022
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of LCAR-AIO in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence, severity, and type of treatment-emergent adverse events at 2 years and Recommended Phase 2 dose finding at 30 days. Started Mar 2022; status: terminated.
02
Drugs
LCAR-AIO
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05292898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292898.